Ocular Therapeutix Inc (OCUL)
8.52
-0.26
(-2.96%)
USD |
NASDAQ |
Nov 21, 16:00
8.89
+0.37
(+4.34%)
Pre-Market: 20:00
Ocular Therapeutix Profit Margin (Quarterly): -236.6% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -236.6% |
| June 30, 2024 | -266.3% |
| March 31, 2024 | -438.9% |
| December 31, 2023 | -197.4% |
| September 30, 2023 | -3.42% |
| June 30, 2023 | -136.2% |
| March 31, 2023 | -226.7% |
| December 31, 2022 | -110.4% |
| September 30, 2022 | -202.2% |
| June 30, 2022 | -153.0% |
| March 31, 2022 | -95.11% |
| December 31, 2021 | -31.28% |
| September 30, 2021 | 21.86% |
| June 30, 2021 | -72.38% |
| March 31, 2021 | 42.51% |
| December 31, 2020 | -1.16K% |
| September 30, 2020 | -203.3% |
| June 30, 2020 | -2.33K% |
| March 31, 2020 | -824.5% |
| December 31, 2019 | -1.15K% |
| September 30, 2019 | -2.27K% |
| June 30, 2019 | -3.76K% |
| Date | Value |
|---|---|
| March 31, 2019 | -3.48K% |
| December 31, 2018 | -3.45K% |
| September 30, 2018 | -3.01K% |
| June 30, 2018 | -2.13K% |
| March 31, 2018 | -4.05K% |
| December 31, 2017 | -2.69K% |
| September 30, 2017 | -2.98K% |
| June 30, 2017 | -4.27K% |
| March 31, 2017 | -3.37K% |
| December 31, 2016 | -2.51K% |
| September 30, 2016 | -2.01K% |
| June 30, 2016 | -2.60K% |
| March 31, 2016 | -2.37K% |
| December 31, 2015 | -2.44K% |
| September 30, 2015 | -2.69K% |
| June 30, 2015 | -2.18K% |
| March 31, 2015 | -1.78K% |
| December 31, 2014 | -1.58K% |
| September 30, 2014 | -5.10K% |
| June 30, 2014 | -6.59K% |
| March 31, 2014 | -25.96K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-2.33K%
Minimum
Jun 2020
42.51%
Maximum
Mar 2021
-389.1%
Average
-199.8%
Median
Profit Margin (Quarterly) Benchmarks
| 4D Molecular Therapeutics Inc | -1.46M% |
| NovaBay Pharmaceuticals Inc | -49.65% |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -70.49% |
| Return on Assets | -44.45% |
| Return on Invested Capital | -54.93% |
| Gross Profit Margin (Quarterly) | 89.88% |
| Operating Margin (Quarterly) | -298.2% |
| Return on Net Operating Assets | -368.4% |